Cencora, Inc. (NYSE:COR) is a prominent player in the healthcare distribution sector, providing pharmaceutical products and services. The company is known for its extensive network and efficient supply chain solutions. Cencora competes with other major distributors like McKesson and Cardinal Health. On February 10, 2026, Wells Fargo maintained its "Overweight" rating for COR, with a "hold" action, and raised its price target from $405 to $429, as highlighted by TheFly.
BI Asset Management Fondsmaeglerselskab A S has shown confidence in Cencora by increasing its holdings by 17.9% during the third quarter. The institutional investor now owns 144,287 shares, having purchased an additional 21,933 shares. This investment is valued at approximately $45 million, representing about 0.07% of Cencora's total market value.
Other investors have also made moves in Cencora. Ameritas Advisory Services LLC acquired a new stake valued at around $157,000 during the second quarter. Simplicity Wealth LLC also purchased a new position worth approximately $555,000 in the same period. Grimes and Company Inc. increased its holdings by 3.6%, now owning 1,272 shares valued at $381,000.
The stock for COR is currently priced at $363.27, reflecting a price change of $4.02, or a 1.119% increase. Today, the stock has fluctuated between a low of $358.94 and a high of $367.28. Over the past year, it has reached a high of $377.54 and a low of $237.71, indicating significant volatility.
Cencora's market capitalization stands at approximately $70.67 billion, with a trading volume of 946,209 shares. This substantial market cap highlights the company's strong position in the industry. The recent price target increase by Wells Fargo suggests optimism about Cencora's future performance.
